---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-303895"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2025-12-01T23:59:59+00:00"
generated_at: "2026-05-16T15:57:40.354119+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "medium"
source: SEC EDGAR
---

# Perspective Therapeutics updates corporate presentation; highlights pipeline progress

## Summary
- Updated presentation covers [212Pb]VMT-α-NET Phase 1/2a for NETs and [212Pb]VMT01 for melanoma.
- Claims compelling anti-tumor activity, durable disease control, and best-in-class safety for NET trial.
- Presentation notes upcoming data milestones but no specific dates or new financial guidance.
- Pipeline includes PSV359 targeting FAP-α; supply chain with on-demand regional sites.
- No material changes to business or financials disclosed in the 8-K.

## SEC filing metadata
- accession: 0001193125-25-303895
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2025-12-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000119312525303895/0001193125-25-303895-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000119312525303895/catx-20251201.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-303895
- JSON: https://secwatch.observer/filing/0001193125-25-303895.json
- Plain text: https://secwatch.observer/filing/0001193125-25-303895.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.